Pancreatic Cancer Research

ResearcherTokai UniversityActive in the last 2 years

Masaki Mori

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5111584585. Sources: OpenAlex.

Their work

Papers
22 (first author 0, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
57
Papers, trials and grants by year

2011: 2 papers · 2012: none · 2013: 2 papers · 2014: none · 2015: 2 papers · 2016: 1 paper · 2017: 4 papers · 2018: 1 paper · 2019: none · 2020: 4 papers · 2021: 3 papers · 2022: none · 2023: none · 2024: 2 papers · 2025: 1 paper

Papers 22

  1. Low Pretreatment CALLY Index Predicts Early Recurrence in Resected UICC Stage I Pancreatic Ductal Adenocarcinoma. Co-author PMID 40105230↗
  2. Impact of the COVID-19 pandemic on short-term outcomes after pancreaticoduodenectomy for pancreatic cancer: A retrospective study from the Japanese National Cl… Co-author DOI 10.1002/ags3.12798↗
  3. Lymphocyte Antigen 6 Family Member D (LY6D) Affects Stem Cell Phenotype and Progression of Pancreatic Adenocarcinoma. Co-author DOI 10.21873/anticanres.17300↗
  4. Prognostic significance of preoperative PNI and CA19-9 for pancreatic ductal adenocarcinoma: A multi-institutional retrospective study. Last author DOI 10.1016/j.pan.2021.08.003↗
  5. Impact of Capicua on Pancreatic Cancer Progression. Last author DOI 10.1245/s10434-020-09339-z↗
  6. ASO Author Reflections: A New Prognostic Factor for Pancreatic Cancer. Last author DOI 10.1245/s10434-020-09386-6↗
  7. Efficacy of Neoadjuvant Chemotherapy in Distal Pancreatectomy with En Bloc Celiac Axis Resection (DP-CAR) for Locally Advanced Pancreatic Cancer. Last author DOI 10.1007/s11605-019-04324-8↗
  8. Mitochondrial expression of the DNA repair enzyme OGG1 improves the prognosis of pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.pan.2020.07.011↗
  9. Anti-glypican-1 antibody-drug conjugate is a potential therapy against pancreatic cancer. Co-author DOI 10.1038/s41416-020-0781-2↗
  10. Genome-wide association meta-analysis identifies GP2 gene risk variants for pancreatic cancer. Co-author DOI 10.1038/s41467-020-16711-w↗
  11. Prolonged Neoadjuvant Therapy for Locally Advanced Pancreatic Cancer. Co-author DOI 10.1159/000475477↗
  12. Preoperative chemoradiotherapy does not compromise the feasibility of adjuvant chemotherapy for patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00595-016-1405-6↗
  13. The basal nutritional state of PDAC patients is the dominant factor for completing adjuvant chemotherapy. Co-author DOI 10.1007/s00595-017-1522-x↗
  14. Fatty Acid-Mediated Stromal Reprogramming of Pancreatic Stellate Cells Induces Inflammation and Fibrosis That Fuels Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000000943↗
  15. [A Case Report of Curative Surgery for Pancreatic Ductal Adenocarcinoma with Peritoneal Dissemination after Gemcitabine Chemotherapy]. Co-author PMID 29394852↗
  16. [Long-Term Survival after Locally Advanced Pancreatic Ductal Adenocarcinoma Treated with Multidisciplinary Therapy - A Case Report]. Co-author PMID 28133093↗
  17. Survival Impact of Pulmonary Metastasis as Recurrence of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1159/000439545↗
  18. [Three Resected Cases of Metachronous Pancreatic Cancer Successfully Treated with Repeated Pancreatectomy]. Co-author PMID 26805359↗
  19. Preoperative chemoradiotherapy, surgery and adjuvant therapy for resectable pancreatic cancer. Co-author DOI 10.5754/hge12974↗
  20. [Pancreatic cancer showing complete pathological response to preoperative chemoradiotherapy-a case report]. Co-author PMID 24393950↗
  21. [Multicenter phase II study of pre-administered uracil/tegafur (UFT) plus gemcitabine for unresectable/recurrent pancreatic cancer]. Co-author PMID 21566438↗
  22. [A case report of port-site metastasis of pancreatic cancer after laparoscope assistted distal pancreatectomy]. Co-author PMID 22202411↗

Closest collaborators

The 25 strongest of 57 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yuichiro Doki · 14 shared papers, 2011–2024 · strength 0.84
  2. Hidetoshi Eguchi · 12 shared papers, 2011–2024 · strength 0.76
  3. Tomoharu Yoshizumi · 5 shared papers, 2020–2021 · strength 0.61
  4. Shinji Itoh · 5 shared papers, 2020–2021 · strength 0.61
  5. Shohei Yoshiya · 4 shared papers, 2020–2021 · strength 0.50
  6. Tadafumi Asaoka · 8 shared papers, 2015–2018 · strength 0.45
  7. Daisaku Yamada · 7 shared papers, 2015–2018 · strength 0.41
  8. Kunihito Gotoh · 5 shared papers, 2017–2018 · strength 0.31
  9. Toshio Nakagohri · 1 shared paper, 2025 · strength 0.26
  10. Shigenori Ei · 1 shared paper, 2025 · strength 0.26
  11. Shinichiro Takahashi · 1 shared paper, 2025 · strength 0.26
  12. Taro Mashiko · 1 shared paper, 2025 · strength 0.26
  13. Masahiro Tanemura · 5 shared papers, 2011–2018 · strength 0.25
  14. Yutaka Takeda · 5 shared papers, 2011–2018 · strength 0.25
  15. Yoshinao Oda · 2 shared papers, 2020–2021 · strength 0.21
  16. Kyohei Yugawa · 2 shared papers, 2020–2021 · strength 0.21
  17. Keishi Sugimachi · 2 shared papers, 2020–2021 · strength 0.20
  18. Tomohiro Iguchi · 2 shared papers, 2020–2021 · strength 0.20
  19. Toru Ikegami · 2 shared papers, 2020 · strength 0.19
  20. Shoichi Inokuchi · 2 shared papers, 2020 · strength 0.19
  21. Yoshifumi Iwagami · 3 shared papers, 2017–2018 · strength 0.18
  22. Shumpei Okimura · 1 shared paper, 2024 · strength 0.18
  23. Hirofumi Yamamoto · 1 shared paper, 2024 · strength 0.18
  24. Yasuyuki Seto · 1 shared paper, 2024 · strength 0.18
  25. Yuhki Yokoyama · 1 shared paper, 2024 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.